Dr. Sultan Darvesh, a neurologist, chemist and professor at Dalhousie University, is unlocking the mystery behind Alzheimer's Disease.

While there is limited data on the prevalence and severity of COVID-19 among pregnant women, it is thought that they could be at risk of serious complications from COVID-19.

The Dalhousie University Faculty of Medicine has partnered with the MacEachen Institute for Public Policy and Governance (MIPP) in a move to facilitate the Faculty’s strategic vision for improving health in the Maritimes.

There was also a virtual teach-in for Black lives hosted by Dal’s James R. Johnston Chair in Black Canadian Studies OmiSoore Dryden and Halifax poet, scholar and activist El Jones that included scholars from Dalhousie as well as peer institutions across Nova Scotia.

Train med-school residents in these rural communities, so they live, work, connect with the community and, in turn, become a part of that community themselves. The result? They choose to stay.

On Thursday, October 1, Canada's COVID-19 Immunity Task Force (CITF) announced its support for a new SARS-CoV-2 study focused on aging Canadians

The start of a new academic year is always a special time at Dalhousie Medicine New Brunswick (DMNB) and the ongoing pandemic did nothing to change that. Despite things looking a little different than they have in years previous, DMNB was still able to welcome a new cohort of students into the study of medicine with one of its flagship events: the annual First Light Ceremony.

This year's recipients of Dalhousie's top honour for alumni include chemist and neurologist Sultan Darvesh (MD’88); Stantec Vice-President of Practice Services and Indigenous Relations Denise Pothier (BEng’93), accountant and community leader Doug Reid (BComm’82); and health-care leader and philanthropist Robert Zed (MHS’86).

As he nears the start of his own independent practice, Dr. Henry Annan is taking time away from his residency to complete the Master of Public Policy (MPP) program at Oxford University.

Dr. Shashi Gujar, a scientist with the Department of Pathology at Dal, together with partners in France, Demark, Germany, the United States and India, is examining whether the immune response to SARS-CoV-2 could be repurposed as the next generation of cancer immunotherapy.